Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation.
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 12 Mar 2011 New trial record